J
Jesse Weinberger
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 97
Citations - 7904
Jesse Weinberger is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Stroke & Ischemia. The author has an hindex of 32, co-authored 97 publications receiving 7212 citations. Previous affiliations of Jesse Weinberger include Mount Sinai Health System.
Papers
More filters
Journal ArticleDOI
Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young.
Thomas J Oxley,J Mocco,Shahram Majidi,Christopher P. Kellner,Hazem Shoirah,I. Paul Singh,Reade De Leacy,Tomoyoshi Shigematsu,Travis R. Ladner,Kurt A. Yaeger,Maryna Skliut,Jesse Weinberger,Neha S. Dangayach,Joshua B. Bederson,Stanley Tuhrim,Johanna T Fifi +15 more
TL;DR: Five patients younger than 50 years of age with large-vessel stroke and Covid-19 infection presented to a health system in New York City over a 2-week period with signs of stroke and infection.
Journal ArticleDOI
Strategies for Multivessel Revascularization in Patients with Diabetes
Michael E. Farkouh,Michael J. Domanski,Lynn A. Sleeper,Flora S. Siami,George Dangas,Michael J. Mack,David J. Cohen,Yves Rosenberg,Scott D. Solomon,Akshay S. Desai,Bernard J. Gersh,Elizabeth A. Magnuson,Alexandra J. Lansky,Robin Boineau,Jesse Weinberger,Krishnan Ramanathan,J. Eduardo Sousa,Jamie Rankin,Balram Bhargava,John B. Buse,Whady Hueb,Craig R. Smith,Victoria Muratov,Sameer Bansilal,Spencer B. King,Michel E. Bertrand,Valentin Fuster +26 more
TL;DR: For patients with diabetes and advanced coronary artery disease, CABG was superior to PCI in that it significantly reduced rates of death and myocardial infarction, with a higher rate of stroke.
Journal ArticleDOI
Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke prevention in Atrial Fibrillation III Randomised Clinical Trial
Joseph L. Blackshear,Vickie S. Baker,F. Rubino,Robert E. Safford,Gary E. Lane,T. Flipse,J. Malouf,Randall C. Thompson,Richard Webel,Greg C. Flaker,L. Young,David C Hess,G. Friedman,R. Burger,John H. McAnulty,Bruce M. Coull,Christy Marchant,J. Timberg,C. Janzik,G. Giraud,B. Halperin,J. Kron,M. Wynn,M. Raitt,David C. Anderson,Richard W. Asinger,S. M. Newburg,J. Fifield,S. R. Bundlie,Richard L. Koller,R. D. Tarrel,C. Dick,J. M. Haugland,C. R. Jorgensen,Anne D. Leonard,Merrill C. Kanter,Diane H. Solomon,Miguel Zabalgoitia,D. Mego,John E. Carter,S. Y. Boyd,Bradley S. Boop,D. LaLonde,R. Modlin,William R. Logan,B. J. Green,William P. Hamilton,L. Mezei,S. Riggio,George Feldman,Arthur D. Hayward,R. Strauss,W. Anderson,J. Grover,M. McKenzie,P. Hart-McArthur,M. Gramberg,H. Houston,Jonathan L. Halperin,E. B. Rothauf,Jesse Weinberger,Martin E. Goldman,Andreas Laupacis,K. L. Chan,P. Bourque,J. Biggs,A. Ives,William M. Feinberg,Karl B. Kern,Gregory D. Pennock,Paul E. Fenster,B. J. Huerta,J. Ohm,Howard C. Dittrich,C. Kerridge,W. Keen,M. Swenson,Stephen L. Kopecky,Scott C. Litin,David O. Wiebers,Anne E. Holland,Ronald D. Brown,B. K. Khandheria,I. Meissner,K. R. Tucker,Robert M. Rothbart,J. Torelli,J. Schmidt,D. Murray,R. S. Ruzich,H. Loutfi,Christopher P. Appleton,T. Ingall,L. Carlson,D. Wilson,M. Dunn,B. Nolte,C. Edwards,A. Dick,L. A. Price,Denise L. Janosik,P. Bjerregaard,A. Quattromani,L. Schiller,Arthur J. Labovitz,C. Burch,B. J. Parks,D. Thompson,L. Berarducci,S. Carey,A. Vigil,Rodney H. Falk,N. Battinelli,M. McNeil,R. Davidoff,Sheilah Bernard,P. Bergethon,L. Fiori,Gregory W. Albers,E. Atwood,J. Clark,D. Tong,Midori A. Yenari,V. Froelicker,H. Lutsep,N. H. Hock,S. Quaglietti,S. Kemp,M. A. Alpert,J. F. Rothrock,C. H. Hupp,C. V. Massey,W. J. Hamilton,V. T. Miller,J. Fox,RichardA. Kronmal,Ruth McBride,E. Nasco,Lesly A. Pearce,K. Fletcher,Jodi Koehler,Robert G. Hart,David G. Sherman,R. L. Talbert,P. A. Heberling,C. Kajzer,EG Bovill,D. Geffken,E. Cornell,S. Nightingale,S. P. Kelsy,David E. Levy,J. D. Marsh,K. M.A. Welch,John R. Marler,M. D. Walker +155 more
TL;DR: Low-intensity, fixed-dose warfarin plus aspirin in this regimen is insufficient for stroke prevention in patients with non-valvular AF at high-risk for thromboembolism; adjusted-doseWarfarin (target INR 2.0-3.0) importantly reduces stroke for high- risk patients.
Journal ArticleDOI
Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging.
Roberto Corti,Valentin Fuster,Zahi A. Fayad,Stephen G. Worthley,Gérard Helft,Donald R. Smith,Jesse Weinberger,Jolanda J. Wentzel,Gabor Mizsei,Michele Mercuri,Juan J. Badimon +10 more
TL;DR: The present study demonstrates that maintained lipid-lowering therapy with simvastatin is associated with significant regression of established atherosclerotic lesions in humans and indicates that lipid- Lowering therapy isassociated with sustained vascular remodeling and emphasize the need for longer-term treatment.
Journal ArticleDOI
Effects of Aggressive Versus Conventional Lipid-Lowering Therapy by Simvastatin on Human Atherosclerotic Lesions: A Prospective, Randomized, Double-Blind Trial With High-Resolution Magnetic Resonance Imaging
Roberto Corti,Valentin Fuster,Zahi A. Fayad,Stephen G. Worthley,Gérard Helft,William F. Chaplin,Jörg Muntwyler,Juan F. Viles-Gonzalez,Jesse Weinberger,Donald A. Smith,Gabor Mizsei,Juan J. Badimon +11 more
TL;DR: Effective and protracted lipid-lowering therapy with simvastatin is associated with a significant regression of atherosclerotic lesions.